274 related articles for article (PubMed ID: 36011286)
21. MiR-30e-3p Influences Tumor Phenotype through
Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
[TBL] [Abstract][Full Text] [Related]
22. Downregulated miR-23b-3p expression acts as a predictor of hepatocellular carcinoma progression: A study based on public data and RT-qPCR verification.
He RQ; Wu PR; Xiang XL; Yang X; Liang HW; Qiu XH; Yang LH; Peng ZG; Chen G
Int J Mol Med; 2018 May; 41(5):2813-2831. PubMed ID: 29484429
[TBL] [Abstract][Full Text] [Related]
23. Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib.
Zhang Y; Pan Q; Shao Z
Hum Cell; 2023 Jan; 36(1):296-311. PubMed ID: 36424471
[TBL] [Abstract][Full Text] [Related]
24. CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress.
Lu Y; Chan YT; Wu J; Feng Z; Yuan H; Li Q; Xing T; Xu L; Zhang C; Tan HY; Lee TK; Feng Y; Wang N
Drug Resist Updat; 2023 Nov; 71():101015. PubMed ID: 37924725
[TBL] [Abstract][Full Text] [Related]
25. Exosomal miR-93 derived from hepatocellular carcinoma cell promotes the sorafenib resistance of hepatocellular carcinoma through PTEN/PI3K/Akt pathway.
Bao Y; Xu S; Zhou J; Zhao C; Dai S; Zhang Y; Rao M
J Biochem Mol Toxicol; 2024 Mar; 38(3):e23666. PubMed ID: 38375688
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.
Vaira V; Roncalli M; Carnaghi C; Faversani A; Maggioni M; Augello C; Rimassa L; Pressiani T; Spagnuolo G; Di Tommaso L; Fagiuoli S; Rota Caremoli E; Barberis M; Labianca R; Santoro A; Bosari S
Liver Int; 2015 Mar; 35(3):1077-86. PubMed ID: 25040368
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.
Awan FM; Naz A; Obaid A; Ikram A; Ali A; Ahmad J; Naveed AK; Janjua HA
Sci Rep; 2017 Sep; 7(1):11448. PubMed ID: 28904393
[TBL] [Abstract][Full Text] [Related]
28. The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating
Wang S; Liu D; Wei H; Hua Y; Shi G; Qiao J
Bioengineered; 2022 Feb; 13(2):2272-2284. PubMed ID: 35034536
[TBL] [Abstract][Full Text] [Related]
29. MiR-21-5p promotes sorafenib resistance and hepatocellular carcinoma progression by regulating SIRT7 ubiquitination through USP24.
Hu Z; Zhao Y; Mang Y; Zhu J; Yu L; Li L; Ran J
Life Sci; 2023 Jul; 325():121773. PubMed ID: 37187452
[TBL] [Abstract][Full Text] [Related]
30. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-520c-3p Modulates Doxorubicin-Chemosensitivity in HepG2 Cells.
Ragheb MA; Soliman MH; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
Anticancer Agents Med Chem; 2021; 21(2):237-245. PubMed ID: 32357822
[TBL] [Abstract][Full Text] [Related]
32. MiR-3677-3p promotes development and sorafenib resistance of hepatitis B-related hepatocellular carcinoma by inhibiting FOXM1 ubiquitination.
He H; Zhou J; Cheng F; Li H; Quan Y
Hum Cell; 2023 Sep; 36(5):1773-1789. PubMed ID: 37402927
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma.
Komoll RM; Hu Q; Olarewaju O; von Döhlen L; Yuan Q; Xie Y; Tsay HC; Daon J; Qin R; Manns MP; Sharma AD; Goga A; Ott M; Balakrishnan A
J Hepatol; 2021 Jan; 74(1):122-134. PubMed ID: 32738449
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib.
Manganelli M; Grossi I; Ferracin M; Guerriero P; Negrini M; Ghidini M; Senti C; Ratti M; Pizzo C; Passalacqua R; Molfino S; Baiocchi G; Portolani N; Marchina E; De Petro G; Salvi A
Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356875
[TBL] [Abstract][Full Text] [Related]
35. Combining Everolimus and Ku0063794 Promotes Apoptosis of Hepatocellular Carcinoma Cells via Reduced Autophagy Resulting from Diminished Expression of miR-4790-3p.
Choi HJ; Park JH; Kim OH; Kim KH; Hong HE; Seo H; Kim SJ
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799789
[TBL] [Abstract][Full Text] [Related]
36. MiR-490-3p inhibits autophagy via targeting ATG7 in hepatocellular carcinoma.
Ou Y; He J; Liu Y
IUBMB Life; 2018 Jun; 70(6):468-478. PubMed ID: 29676845
[TBL] [Abstract][Full Text] [Related]
37. Effects of miR-193a and sorafenib on hepatocellular carcinoma cells.
Salvi A; Conde I; Abeni E; Arici B; Grossi I; Specchia C; Portolani N; Barlati S; De Petro G
Mol Cancer; 2013 Dec; 12():162. PubMed ID: 24330766
[TBL] [Abstract][Full Text] [Related]
38. LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells.
Sun J; Zheng X; Wang B; Cai Y; Zheng L; Hu L; Lu X; Xie S; Zhang X; Liu H; Ye L
Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(2):261-270. PubMed ID: 35130616
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma.
Soliman MH; Ragheb MA; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
Anticancer Agents Med Chem; 2021; 21(2):246-253. PubMed ID: 32416702
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
Zhai B; Hu F; Jiang X; Xu J; Zhao D; Liu B; Pan S; Dong X; Tan G; Wei Z; Qiao H; Jiang H; Sun X
Mol Cancer Ther; 2014 Jun; 13(6):1589-98. PubMed ID: 24705351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]